| Gene Symbol | AD |
| Discrimination accuracy | AUC 0.95-0.97 for distinguishing AD from other neurodegenerative conditions, outperforming all other blood biomarkers[@sunderland2024] |
| Correlation with amyloid | Strong correlation (r = 0.7-0.8) with PET amyloid burden across multiple cohorts |
| Longitudinal changes | Tracks disease progression over time, with annual increases of 8-12% in converters from MCI to AD |
| Clinical utility | Suitable for primary care screening, with point-of-care platforms in development |
| Platform availability | Available on Roche, Fujirebio, and Simoa platforms, with FDA submission expected in 2026 |
| Widely validated | Multiple independent cohorts including over 10,000 participants |
| Detection threshold | Can detect amyloid positivity before clinical symptoms, with 85% sensitivity in preclinical AD |
| Platform comparisons | Simoa, Lumipulse, and mass spectrometry approaches all show robust performance |
| Clinical availability | Most widely available p-tau assay, with FDA-cleared tests already in use |
| Early detection | Changes occur before p-tau181 in the disease course, potentially 5-10 years earlier |
| Specificity | Highly specific for AD pathology, with less elevation in other tauopathies |
| Combination potential | Best used in combination with other markers for comprehensive assessment |
| Research status | Primarily available in research settings, clinical implementation pending |
| Reduced ratio | Reflects brain amyloid deposition, with approximately 30-40% reduction in AD patients |
| FDA-approved assays | Commercial platforms now available from Roche and Fujirebio |
| Associated Diseases | DEMENTIA, T2D, T2DM |
| KG Connections | 1498 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
No AI portrait yet
No comments yet. Be the first to comment!